Hungary has granted China's CanSino vaccine emergency use authorisation, making it the second China-developed Covid-19 vaccine approved in the European country, Hungarian Chief Medical Officer Cecilia Muller said.
Apart from the CanSino vaccine, the National Institute of Pharmacy and Nutrition has also approved the import of CoviShield, the Indian version of the AstraZeneca vaccine, Muller told a news conference, Xinhua news agency reported on Tuesday.
"We will search the four corners of the world to have enough vaccines in the country," she said.
The Hungarian government has been enriching its inoculation program with multiple vaccines in the fight against a third wave of the pandemic. So far, it has gained access to vaccines from five producers worldwide, including China's Sinopharm.
The use of Russian and Chinese vaccines has greatly contributed to the acceleration of the Hungarian vaccine program, according to Hungarian Minister of Foreign Affairs and Trade Peter Szijjarto.
"Vaccine is not a question of ideology for us; it is a matter of saving lives. And if we had not contracted Chinese and Russian vaccines, we could not have saved the health and lives of so many Hungarians," the minister said in a recent interview with Russia Today.
Hungary, the first European Union member state to purchase a Chinese vaccine and authorize its use, started to administer the Sinopharm vaccine on February 24.
--IANS
int/
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)